Loading clinical trials...
Loading clinical trials...
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12)
Conditions
Interventions
Belantamab mafodotin
Locations
19
United States
GSK Investigational Site
Tucson, Arizona, United States
GSK Investigational Site
Beverly Hills, California, United States
GSK Investigational Site
Sacramento, California, United States
GSK Investigational Site
Jacksonville, Florida, United States
GSK Investigational Site
Plantation, Florida, United States
GSK Investigational Site
Chicago, Illinois, United States
Start Date
October 9, 2020
Primary Completion Date
April 21, 2025
Completion Date
December 31, 2025
Last Updated
May 23, 2025
NCT07249528
NCT06215118
NCT06679101
NCT05969860
NCT06383143
NCT06870760
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions